Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 10
ASCO Insights: Experts Discuss Recent DREAMM-7 and DREAMM-8 Data
Panelists discuss how updated data from the DREAMM-7 and DREAMM-8 studies validate the early integration of BCMA-targeted therapies like belantamab mafodotin, showing promising efficacy and manageable ocular toxicities.
DREAMM Studies Highlight Role of Belantamab in Earlier Lines
Updated analyses from the DREAMM-7 and DREAMM-8 trials reinforce the clinical benefit of using belantamab mafodotin in combination with standard backbones in early relapsed disease. These regimens produce durable responses and are generally well-tolerated.
Belantamab’s unique mechanism as an antibody-drug conjugate allows for convenient off-the-shelf use, making it particularly appealing in community settings. While ocular toxicity remains a concern, new data suggest these adverse effects are often reversible and manageable with supportive care.
These studies lay the groundwork for incorporating belantamab into earlier treatment lines, potentially improving access to potent anti-BCMA therapy while reducing infection risks associated with T cell–redirecting therapies.
Related Content:
